By Abionic
The abioSCOPE®, a near-patient rapid in vitro diagnostic platform, integrates seamlessly into clinical workflows. Nanofluidic immunoassay technology enables the abioSCOPE® to deliver lab-quality quantitative, semi-quantitative, or qualitative results within minutes from a single drop (50 µL) of whole blood. The device reads a cartridge containing test-specific biosensors, ensuring reliable performance and enabling accurate diagnostic decisions. The abioSCOPE ® - a Benchtop Platform: - Results within minutes near-patient - Seamless integration into Hospital/Laboratory Systems - No sample-to-device contamination ONE DROP OF WHOLE BLOOD: 50 μl of blood (capillary, venous or arterial whole blood) to perform a test on the abioSCOPE ®. LAB-QUALITY RESULTS WITHIN MINUTES: abioSCOPE ® provides highly accurate, actionable results. abioSCOPE® EASY DEVICE HANDLING: Low-maintenance and no sample-to-device contamination.
The Disposable Cartridge: Based on Nanofluidic Immunoassay; Single-cartridge multiplex testing; Lab-Quality Results. The device reads a cartridge containing test-specific biosensors, ensuring reliable performance and enabling accurate diagnostic decisions.
CATEGORY
Used in combination with qSOFA/NEWS-2 scores, a PSP measure can double the "Rule-In" performance and empower frontline workers to accelerate the activation of time-critical Sepsis bundles. PSP Benefits: - Improves qSOFA/NEWS-2 sepsis assessments for a better patient stratification / Rule-In Performance - Helps resolve clinical uncertainty when screening scores are borderline (qSOFA ≤1, NEWS-2 ≤7) - Early Sepsis Recognition, due to PSP levels that rise up-to 72hrs before Clinical Recognition Not available for sale in the US. Critical Care: PSP enhances real-time sepsis monitoring in critical care: - Discriminates between septic and non-septic cases - Predicts clinical deterioration 72h before standard of care - Reduces unnecessary antibiotic use in patients with non-infectious SIRS Ward: PSP enhances sepsis monitoring when combined with clinical assessment (eg. SOFA/NEWS-2) to support critical decisions. This integrated approach improves early detection of deteriorating patients while enhance the current standard of care. - Early detection of sepsis before clinical recognition - Identifies patients requiring ICU-level care earlier than standard of care - Reduces unnecessary antibiotic use in patients with non-infectious SIRS Available for sale in the US.
CATEGORY
